JPRN-UMIN000028153已完成未知
Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital - Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients suspected of having secondary diabetes (ex. endocrine disease, drug-induced or liver disease) 2) Females who are pregnant or who intend to become pregnant within the study 3) Severe hepatic disease, malignancy, a history of gastrectomy and/or positive for HIV 4) Contraindication with dapagliflozin 5) Patient who disqualified from the study by the investigator for any reason other than given above.
研究者
相似试验
已完成
不适用
Patient Reported Outcome study of Dapagliflozin on glycemic control and treatment satisfaction in overweight patients with type 2 diabetes mellitusOverweight patients with type 2 diabetes mellitusJPRN-UMIN000016304Japan society for Patient Reported Outcome220
尚未招募
不适用
Benefits and side effects of Dapagliflozin medicine in diabetic patients with kidney disease.CTRI/2022/09/045596Maulana Azad Medical College Delhi
尚未招募
不适用
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R
招募中
不适用
Examination of the efficacy of dapagliflozin in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000021954Tonami general hospital Department of diabetes mellitus and endocrinology200
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500